Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Energy metabolism enzymes in Leishmania species comprise a set of essential enzymes responsible for generating ATP and maintaining vital cellular functions through glycolysis, amino acid oxidation, fatty acid β-oxidation, and the electron transport chain[1][2][6]. These include, but are not limited to, hexokinase, phosphofructokinase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, ATP synthase, sterol 24-C-methyltransferase, pyruvate phosphate dikinase, and notably, enzymes specific to trypanothione and redox metabolism like trypanothione synthetase and trypanothione reductase[1][4][6][7]. Many of these enzymes differ significantly in sequence or structure from human equivalents, making them attractive targets for new anti-leishmanial drugs[4][5][7]. Several, such as trypanothione reductase and sterol 24-C-methyltransferase, have been prioritized for drug development, and species-specific abundance of these enzymes also serves as a biomarker for diagnostics[2][4][7]. However, targeting these enzymes may also raise challenges around metabolic plasticity and potential cross-reactivity with human enzymes[5][6][7]. Key examples of individual targets within this group: - Trypanothione reductase: Central for redox balance, unique to trypanosomatids, intensively pursued as a therapeutic target with several inhibitors under study[7]. - Sterol 24-C-methyltransferase: Essential for ergosterol synthesis; inhibited by azasterols[4]. - Hexokinase/Phosphofructokinase/Glycolytic enzymes: Involved in the parasite’s main ATP generating pathway, with expression shifting across life stages[1][6]. Because the term encompasses multiple molecular entities, for structured databases it is better to enumerate these enzymes individually per the conventions noted above.
Inhibition of ATP production; Blockade of ergosterol biosynthesis (e.g., sterol 24-C-methyltransferase inhibition); Disruption of redox balance (e.g., trypanothione pathway inhibitors)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Energy metabolism enzyme (Leishmania) (null).